Moderna’s second-quarter revenue jumps fivefold on coronavirus vaccine development

Revenue jumped to $66.4 million during the quarter, more than five times the $13.1 million it took in during the same period last year.
The company narrowed its second-quarter loss to $116.7 million, or 31 cents a share, from $134.9 million, or 41 cents a share during the same quarter last year.
The company’s already received about $400 million in deposits to supply its vaccine as of July 31.